NY-AQARA
Aqara, a leading provider of smart home solutions, today announced the availability of the Motion and Light Sensor P2, its new generation motion sensor built upon the Thread protocol and the industry-unifying Matter standard. The native Matter connectivity offers unparalleled compatibility across smart home platforms including Amazon Alexa, Apple Home, Google Home, and Samsung SmartThings1. With Matter's local networking capabilities, the P2 sensor ensures enhanced responsiveness and reliability.
“In the rapidly expanding global market for Passive Infrared (PIR) sensors, Aqara has achieved remarkable success, distributing over 100,000 units last year,” states Cathy You, Aqara Senior Vice President, Global Business and Strategy. “The launch of the Motion and Light Sensor P2, which combines our renowned sensor technology with the latest in connectivity protocols and standards, encapsulates our forward-thinking approach and our commitment to delivering smart home solutions that are ready for tomorrow's advancement.”
The Motion and Light Sensor P2 integrates an ultra-wide angle PIR motion sensor with a standalone illumination sensor, providing precise detection up to 7 meters (ca. 23 feet) and 170° horizontally2. This facilitates a range of use scenarios from automated lighting and security enhancement to climate control. The sensor also measures light intensity independently of motion detection3, enabling sophisticated lighting and window covering control for optimal comfort and energy efficiency. Engineered for longevity, the Motion and Light Sensor P2 boasts a robust battery life of up to two years, ensuring dependable operation with minimal maintenance.
As a Thread-enabled device, the Motion and Light Sensor P2 connects to any Matter controller with Thread Border Router functionality, and allows use across multiple compatible platforms thanks to Matter's multi-admin feature. Furthermore, the sensor offers a few Aqara Home exclusive features such as customizable sensitivity and detection timeout settings for tailored performance4. Users can fine-tune both parameters through the Aqara Home app, which requires Aqara's own Thread-enabled Matter controller, for example the upcoming Hub M3.
As part of Aqara’s expanding Thread-enabled product line, the Motion and Light Sensor P2 exemplifies the Company’s dedication to elevating smart home experiences through enhanced interoperability and simplicity. Additional Thread devices from Aqara are expected in the coming months, including the aforementioned Hub M3 and the retrofit home access solution Smart Lock U200.
The Motion and Light Sensor P2 is now available in Aqara’s Amazon brand stores in North America (US, Canada), Europe (France, Germany, Italy, Poland, Spain, UK) and Asia (Japan), as well as through select Aqara retailers worldwide5.
For more information on this sensor, please visit our website.
1. A Matter controller with Thread Border Router functionality is required for the connection to the corresponding Matter-enabled system.
2. Based on the internal lab test, measured under the ambient temperature of 25 °C (ca. 77 °F) and high sensitivity level.
3. Illumination sensing functionality is not available on Alexa at the time of launch.
4. By default, the sensor is set to medium sensitivity and a 30-second detection timeout.
5. Product availability may vary by retail channel.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409809799/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom